A
Abderrahim Fandi
Researcher at Novartis
Publications - 10
Citations - 3777
Abderrahim Fandi is an academic researcher from Novartis. The author has contributed to research in topics: Gefitinib & Lung cancer. The author has an hindex of 6, co-authored 7 publications receiving 3715 citations. Previous affiliations of Abderrahim Fandi include AstraZeneca & University of Turin.
Papers
More filters
Journal ArticleDOI
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
Giuseppe Giaccone,Roy S. Herbst,Christian Manegold,Giorgio V. Scagliotti,Rafael Rosell,Vincent A. Miller,Ronald B. Natale,Joan H. Schiller,Joachim von Pawel,Anna Pluzanska,Ulrich Gatzemeier,John Grous,Judith S. Ochs,Steven D. Averbuch,Michael K. Wolf,Pamela Rennie,Abderrahim Fandi,David H. Johnson +17 more
TL;DR: Gefitinib in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced NSCLC did not have improved efficacy over gemcitABine and cascplatin alone, and the reasons for this remain obscure and require further preclinical testing.
Journal ArticleDOI
Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2
Roy S. Herbst,Giuseppe Giaccone,Joan H. Schiller,Ronald B. Natale,Vincent A. Miller,Christian Manegold,Giorgio V. Scagliotti,Rafael Rosell,Ira Oliff,James A. Reeves,Michael K. Wolf,Annetta D. Krebs,Steven D. Averbuch,Judith S. Ochs,John Grous,Abderrahim Fandi,David H. Johnson +16 more
TL;DR: This large, placebo-controlled trial confirmed the favorable gefitinib safety profile observed in phase I and II monotherapy trials and showed no added benefit in survival, time to progression, response rate (TTP), or RR compared with standard chemotherapy alone.
Journal ArticleDOI
Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung Cancer
Primo N. Lara,Jean-Yves Douillard,Kazuhiko Nakagawa,Joachim von Pawel,Mark J. McKeage,I. Albert,György Losonczy,Martin Reck,Dae Seog Heo,Xiaolin Fan,Abderrahim Fandi,Giorgio V. Scagliotti +11 more
TL;DR: The addition of ASA404 to carboplatin and paclitaxel, although generally well tolerated, failed to improve frontline efficacy in advanced NSCLC.
Journal ArticleDOI
P-615 Phase II trials of gefitinib (‘Iressa’, ZD1839): rapid and durable objective responses in patients with advanced non-small-cell lung cancer (IDEAL 1 and IDEAl 2)
Masahiro Fukuoka,Mark G. Kris,Giuseppe Giaccone,Thomas R. Lynch,Kazuhiko Nakagawa,Karen Kelly,Michael K. Wolf,Angela McPartlane,Andrea C. Kay,Abderrahim Fandi +9 more
Journal ArticleDOI
Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy.
Giuseppe Giaccone,Renee Iacona,Abderrahim Fandi,Abderrahim Fandi,Abderrahim Fandi,Mette S. Janas,Judith S. Ochs,Roy S. Herbst,David H. Johnson +8 more
TL;DR: Analysis of analyses provides statistically significant evidence that the combination of EGFR expression and growth pattern is a strong prognostic indicator for improved survival within this setting.